DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

Scientists tested a wearable blood sugar monitor on adults who weren't taking insulin. The results revealed a measurable ...

DexCom (DXCM) shares spiked on Thursday after The New England Journal of Medicine published results from the company's CONNECT trial for its G7 insulin pump in type 2 diabetes, supporting potential ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Adults with type 2 diabetes who don't use insulin lowered their A1C by 0.9 percentage points more with a continuous glucose monitor (CGM) than with routine care over 26 weeks, according to results ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. Dexcom is facing a ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Hello Health Rounds readers. Today we highlight a study that found benefits of wearable glucose monitoring devices for all ...

I started monitoring my blood glucose levels by wearing a Libre while hospitalized after being diagnosed with Type 1 diabetes ...